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Background: In the general population, metabolic syndrome (MetS) is correlated with visceral fat and a risk factor
for cardiovascular disease (CVD); however, little is known about the significance of abdominal fat and its association
with inflammation and medication use in peritoneal dialysis (PD) patients. We investigated the relationship of
visceral fat area (VFA) with C-reactive protein (CRP) levels and medication use in PD patients and followed their
clinical outcomes.
Methods: In a prospective study from February 2009 to February 2012, we assessed diabetes mellitus (DM) status,
clinical and PD-associated characteristics, medication use, CRP levels, components of MetS, and VFA in 183 PD
patients. These patients were categorized into 3 groups based on MetS and DM status: non-MetS (group 1, n = 73),
MetS (group 2, n = 65), and DM (group 3, n = 45). VFA was evaluated by computed tomography (CT) and corrected
for body mass index (BMI).
Results: Patients in group 1 had smaller VFAs than patients in groups 2 and 3 (3.2 ± 1.8, 4.6 ± 1.9, and 4.9 ± 2.0
cm2/[kg/m2], respectively, P < 0.05) and lower CRP levels (0.97 ± 2.31, 1.27 ± 2.57, and 1.11 ± 1.35 mg/dL, respectively,
P < 0.05). VFA increased with the number of criteria met for MetS. After adjusting for age, body weight, and sex,
CRP and albumin levels functioned as independent positive predictors of VFA; on other hand, the use of renin-
angiotensin system blockers was inversely correlated with VFA in PD patients without DM. In the survival analysis,
DM patients (group 3) had the poorest survival among the 3 groups, but no significant differences were found
between groups 1 and 2.
Conclusion: This study showed that VFA and MetS are associated with CRP levels but cannot predict survival in PD
patients without DM. The complex relationship of nutritional parameters to VFA and MetS may explain these
results. The type of antihypertensive medication used was also associated with the VFA. The mechanisms behind
these findings warrant further investigation.
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Visceral fat area (VFA) is known to be correlated strongly
with metabolic syndrome (MetS). In the general popula-
tion, increased VFA is an independent risk factor for ath-
erosclerosis [1-4]. Because VFA plays a key role in the
development of diabetogenic, atherogenic, prothrombotic,
and proinflammatory MetS, VFA reduction has been pro-
posed as a strategy to prevent atherosclerosis in MetS pa-
tients [5].
In patients requiring dialysis, disturbances in lipid and
carbohydrate metabolism, which are common, have beenTable 1 Clinical characteristics and biochemical parameters a
syndrome (MetS, group 1), PD patients with MetS (group 2),
1








Age 51 ± 14
PD vintage (months) 46 ± 45
Body weight (kg) 57 ± 9
Renal KT/V 0.22 ± 0.33
Peritoneal KT/V 1.87 ± 0.41
4-h D/P Cre 0.67 ± 0.10
D4/D0 Glu 0.37 ± 0.07
Glucose exposure (kg/year) 53 ± 19
Dialysate glucose load (g/dL) 1.86 ± 0.33
nPCR (gm/[kg/day]) 1.02 ± 0.19
Albumin (g/mdL) 3.9 ± 0.3
Hemoglobin (g/dL) 10.2 ± 1.2
Creatinine (mg/dL) 11.5 ± 2.9
Glucose (mg/dL) 92 ± 11
Cholesterol (mg/dL) 197 ± 44
Triglyceride (mg/dL) 116 ± 54
HDL (mg/dL) 48 ± 15
LDL (mg/dL) 100 ± 39
AI1 0.36 ± 0.25
AI2 3.31 ± 1.31
CRP (mg/dL) 0.97 ± 2.31
Cardiothoracic ratio (%) 48 ± 7
SFA (cm2/[kg/m2]) 4.8 ± 2.4
TFA (cm2/[kg/m2]) 8.0 ± 3.6
VFA (cm2/[kg/m2]) 3.2 ± 1.8
*P < 0.05 for comparison to group 1 patients by the student t-test.
a P < 0.05 for comparison to group 1 patients by the non-parametric t-test.
SD standard deviation, AI1 log (TG/HDL); AI2 non-HDL cholesterol/HDL, BMI Body m
density lipoprotein, LDL low density lipoprotein, RAS renin-angiotensin system, SFAassociated with VFA and may develop into MetS. In pa-
tients with chronic kidney disease (CKD), a higher body
mass index (BMI) has been reported to be inversely cor-
related with mortality; however, other studies have sug-
gested that body composition is a more accurate
predictor of survival than BMI [6,7].
VFA can be evaluated accurately by computed tomog-
raphy (CT) at the level of the umbilicus. In hemodialysis
(HD) patients, VFA was found to be the best predictor of
atherogenic index (AI), triglyceride (TG) level, and degree of
atherosclerosis after correcting for BMI [8,9]. Inflammationmong peritoneal dialysis(PD) patients without metabolic
and diabetes mellitus (DM) patients (group 3)
2 3
MetS, n = 65 DM, n = 45







53 ± 12 58 ± 11*
49 ± 36 22 ± 19*
61 ± 12* 68 ± 13*
0.17 ± 0.32 0.18 ± 0.23
1.92 ± 0.35 1.79 ± 0.31
0.64 ± 0.09* 0.68 ± 0.11
0.40 ± 0.06* 0.39 ± 0.07
56 ± 20 58 ± 22
1.87 ± 0.31 2.11 ± 0.31
0.93 ± 0.16* 0.90 ± 0.21*
4.1 ± 0.3* 4.0 ± 0.4
10.0 ± 1.6 10.2 ± 1.0
11.2 ± 2.7 10.9 ± 2.6
106 ± 24* 139 ± 52*
202 ± 48 186 ± 41
273 ± 208* 203 ± 133*
37 ± 7* 36 ± 12*
87 ± 42 85 ± 37*
0.80 ± 0.26* 0.67 ± 0.35*
4.58 ± 1.31* 4.42 ± 1.58*
1.27 ± 2.57a 1.11 ± 1.35a
50 ± 7 53 ± 6
6.1 ± 2.0* 7.3 ± 2.8*
10.7 ± 3.4* 12.1 ± 3.8*
4.6 ± 1.9* 4.9 ± 2.0*
ass index, CAD coronary artery disease, CRP C-reactive protein, HDL high
subcutaneous fat area, TFA total fat area, VFA visceral fat area.



















































Figure 1 The relationship between fat area and CRP was
analyzed with Pearson correlation. Different components of
abdominal fat area were all positively correlated with CRP.
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peritoneal dialysis (PD) patients [11], VFA has been found to
be associated with increased levels of inflammatory markers
such as C-reactive protein (CRP).
An increased glucose concentration in peritoneal fluid re-
sults in increased carbohydrate absorption by the peritonealmembrane. The average concentration of glucose in the
peritoneal fluid of a PD patient predicts survival and is asso-
ciated with higher serum glucose levels [12-14]. In one
study, approximately one-third of PD patients without DM
exhibited insulin resistance [15]; other studies have shown a
high incidence (≥50%) of MetS in this population [16,17]. In
PD patients, both insulin resistance and high glucose ab-
sorption lead to increased VFA, and thus are associated with
higher adipokine concentrations than those in individuals
with normal renal function [18]. Therefore, the significant
contribution of VFA to increased BMI and the association
of VFA with CRP make the elucidation of its role in PD pa-
tient outcomes complex.
Some drugs may affect glucose and lipid metabolism
and, therefore, influence abdominal fat. Renin-angiotensin
system (RAS) blockers have been reported to reduce VFA
and decrease vascular inflammation [19,20]. Traditional
beta blockers can reduce insulin sensitivity and increase
the risk of DM and dyslipidemia [21]. Statins are also used
to manage dyslipidemia and insulin resistance [22]. PD pa-
tients commonly use these medications to treat hyperten-
sion, heart disease, or dyslipidemia; however, the effects of
these medications on VFA have never been studied.
This study aimed at clarifying the associations among
VFA, MetS, inflammation, and medication use and their
corresponding effects on PD patient outcomes. We
found that medication use, inflammation, and MetS
were all associated with VFA in the PD population.
Materials and methods
Study design
In February 2009, patients aged >20 years who had
undergone maintenance PD for more than 3 months
were enrolled. Pregnant women and patients who had
undergone CT scanning during the previous 6 months
were excluded. After providing informed consent, each
patient underwent a non-contrast abdominal CT, and a
blood sample was obtained to measure biomarkers. Pa-
tients fasted for 6 hours prior to phlebotomy. The blood
samples were immediately centrifuged at 3,000 rpm and
4°C, and the resulting plasma samples were frozen
at −80°C until analysis.
Ethical considerations
This study was approved by the ethics committee of this
hospital in documents NTUH-REC No. 200808062R and
NTUH-REC No. 201104032RC. As stated, patients pro-
vided written informed consent before they entered the
study.
Assessment of abdominal fat by computed tomography
The imaging of each subject was performed on a 64-MDCT
scanner (LightSpeed VCT; GE Healthcare, Milwaukee, WI),
and the umbilicus cut was analyzed for VFA [23]. Image
Table 2 Correlations between abdominal fat and clinical parameters in non-DM (n = 138) and DM (n = 45) PD patients
Non-DM, n = 138 DM, n = 45
VFA SFA TFA VFA SFA TFA
Sex −0.04 0.31 * 0.17 * 0.02 0.23 0.18
CAD 0.06 0.01 0.04 0.25 0.02 0.15
Hypertension −0.15 0.06 −0.04 0.31 * 0.06 0.20
RAS blocker −0.17 * −0.17 * −0.20 * −0.06 −0.13 −0.13
Beta blocker 0.15 * 0.27 * 0.24 * 0.08 −0.12 −0.04
Statin 0.10 0.14 0.14 −0.08 −0.12 −0.13
Age 0.40 * 0.35 * 0.43 * 0.50 * 0.06 0.31 *
PD vintage 0.00 −0.09 −0.06 −0.20 −0.04 −0.13
Body weight 0.38 * 0.15 0.29 * −0.08 0.37 * 0.23
BMI 0.44 * 0.41 * 0.49 * 0.02 0.54 * 0.41 *
Renal KT/V 0.07 0.15 0.13 0.14 0.05 0.10
Peritoneal KT/V −0.18 * −0.14 −0.18 * −0.12 0.10 0.02
4 hr D/P Cre −0.05 −0.04 −0.05 −0.02 0.19 0.13
D4/D0 Glu 0.15 0.10 0.14 −0.03 −0.15 −0.13
Glucose exposure −0.07 −0.07 −0.08 0.01 0.22 0.16
Dialysate glucose load −0.02 0.02 0.00 0.09 −0.07 0.00
nPCR −0.23 * −0.27 * −0.28 * −0.25 −0.21 −0.28
Albumin 0.22 * 0.06 0.15 0.09 −0.03 0.02
Hemoglobin 0.05 0.03 0.05 0.01 −0.37 * −0.26
Creatinine −0.13 −0.29 * −0.25 * −0.35 * −0.20 −0.32 *
Glucose 0.17 * 0.10 0.15 0.11 0.29 * 0.27
Cholesterol 0.16 0.24 * 0.23 * 0.24 0.22 0.28
Triglyceride 0.27 * 0.12 0.22 * 0.54 * 0.34 * 0.53 *
HDL −0.27 * 0.01 −0.14 −0.26 −0.22 −0.30 *
LDL −0.02 0.06 0.03 −0.11 0.09 0.01
AI1 0.42 * 0.19 * 0.34 * 0.55 * 0.41 * 0.59 *
AI2 0.39 * 0.18 * 0.32 * 0.45 * 0.31 * 0.46 *
LnCRP 0.36 * 0.16 0.29 * 0.02 0.19 0.15
Cardiothoracic ratio (%) 0.25 * 0.32 * 0.33 * 0.32 * 0.23 0.33 *
Abdominal fat was categorized as visceral fat area (VFA), subcutaneous fat area (SFA), and total fat area (TFA), and all were corrected for body mass index (BMI).
* P < 0.05 with Pearson’s correlation.
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Health, Bethesda, MD) was used at an attenuation range
of −50 to −250 Hounsfield units to quantify abdominal adi-
pose tissue areas in cm2. The subcutaneous fat area (SFA)
was clearly visible and defined as the extraperitoneal fat be-
tween skin and muscle. Intra-abdominal tissue at the same
density as SFA was defined as VFA. The total fat area (TFA)
was the sum of SFA and VFA. The images were reviewed by
radiologists who were blinded to the clinical characteristics
of the PD patients. The 3 indicators of fat area were
corrected for BMI (cm2/[kg/m2]) because fat area relates to
body mass [8].
Clinical characteristics and follow-up
Clinical and dialysis data of PD patients were recorded and
included medication (RAS blockers, beta blockers, or statin),results of PD-associated peritoneal equilibration test (PET),
dialysis Kt/V, residual renal function, and normalized protein
catabolic rate (nPCR). Routine biochemical studies were also
recorded and included urea nitrogen, creatinine, albumin,
hemoglobin, CRP, lipid profile, total cholesterol (CHO), tri-
glyceride (TG), high-density lipoprotein (HDL), and low-
density lipoprotein (LDL).
Two atherogenic indices (AIs) were derived from the
lipid profile, according to the following equations: AI1 =
log (TG/HDL) [24] and AI2 = non-HDL cholesterol/
HDL = (T-CHO-HDL)/HDL [8].
The dialysate prescribed to each PD patient during 2009
was also recorded and used to calculate the glucose load in
these patients, as previously described [12-14]. Glucose load
1 represents the average glucose concentration in the total
PD fluid, including extraneal and nutrineal. Glucose load 2
Table 3 Independent determinants of abdominal fat area by multiple linear regression analysis and adjusted for age
and sex in non-DM (A) and DM (B) PD patients
A.
VFA SFA TFA
B ± SE P B ± SE P B ± SE P
Constant −7.58 ± 1.89 < 0.001 −6.86 ± 1.77 < 0.001 −13.34 ± 2.86 < 0.001
Woman 0.51 ± 0.33 0.13 2.64 ± 0.40 < 0.001 2.81 ± 0.62 < 0.001
Age (per 10 years) 0.40 ± 0.10 < 0.001 0.43 ± 0.12 < 0.001 0.76 ± 0.19 < 0.001
BW (per 10 kg) 0.95 ± 0.15 < 0.001 1.26 ± 0.18 < 0.001 2.20 ± 0.27 < 0.001
Creatinine −0.17 ± 0.05 < 0.01 −0.19 ± 0.06 < 0.01 −0.37 ± 0.09 < 0.001
Albumin 0.95 ± 0.37 < 0.05
AI2 0.30 ± 0.09 < 0.001
LnCRP 0.27 ± 0.08 < 0.001 0.43 ± 0.14 < 0.01
RAS blocker −0.62 ± 0.25 < 0.05 −0.92 ± 0.47 0.05
Beta blocker 1.03 ± 0.30 < 0.001 1.35 ± 0.45 < 0.01
Cholesterol (per 10 mg/dL) 0.11 ± 0.05 < 0.05
D4/D0 Glu (per 0.1) 0.67 ± 0.33 < 0.05
R2 0.559 0.476 0.600
B.
VFA SFA TFA
B ± SE P B ± SE P B ± SE P
Constant −0.29 ± 1.30 0.83 −8.10 ± 3.56 < 0.05 −7.60 ± 4.78 0.12
Woman −0.26 ± 0.47 0.59 2.75 ± 0.73 < 0.001 2.57 ± 0.97 < 0.05
Age (per 10 years) 0.71 ± 0.21 < 0.01 0.21 ± 0.33 0.53 0.80 ± 0.44 0.08
Cholesterol (per 10 mg/dL) 0.07 ± 0.02 < 0.001
BW (per 10 kg) 1.28 ± 0.31 < 0.001 1.20 ± 0.41 < 0.01
AI1 2.38 ± 1.02 < 0.05 4.93 ± 1.37 < 0.001
R2 0.445 0.464 0.491
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containing dialysate only.
After they had undergone an abdominal CT, pa-
tients were monitored for the following events:
hospitalization, peritonitis, technique failure, cardio-
vascular disease (CVD), and mortality. Cardiac dis-
ease, cerebrovascular disease, and severe ischemic
events were categorized as CVD. Patients who re-
ceived transplants were censored in technique survival
and mortality. Transplant admissions were not con-
sidered episodes of hospitalization. Follow-up was
continued until February 2012.Metabolic syndrome
MetS was diagnosed according to the definition in
the National Cholesterol Education Program Adult
Treatment Panel III [25], which requires fulfillment of
at least 3 of the following criteria: abnormal waist cir-
cumference, TG >150 mg/dL, HDL < 40 mg/dL in
men or < 50 mg/dL in women, blood pressure >130/
85 mmHg or active treatment with antihypertensiveagents, and fasting blood glucose >100 mg/dL. Be-
cause waist measurements are inaccurate in PD pa-
tients, we substituted BMI >25 kg/m2 for this value,
as has been done in other studies [17].Statistical analysis
All continuous variables are reported as mean ± SD
(with 95% confidence intervals as appropriate), and all
categorical variables are reported as frequencies or
percentages. Comparison between groups was done
using the student t-test, non-parametric test, or one-
way analysis of variance (ANOVA). The differences in
frequency were tested by χ2 analysis. The relationships
between variables were tested by Pearson’s correlation.
The independent determinants of a variable were de-
termined by multiple linear regression analysis. The
adjusted variables were stated for each analysis. Peri-
tonitis incidence in PD patients was compared by
Poisson analysis. Kaplan-Meier survival analysis was
used to compare survival between groups. P values <
0.05 were considered significant. Statistical analyses


















































Figure 2 The fat area increased as the increment of number of
metS criterion in each component of fat area (A) VFA, (B) SFA,
and (C) TFA (p < 0.001 with ANOVA). The DM patients was
categorized as another group in the last bar.
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Results
Clinical and PD-associated parameters among patients
A total of 183 PD patients were enrolled in this study.
There were 146 patients without DM who were furtherclassified as non-MetS (n = 73, group 1) or MetS (n = 65,
group 2). The remaining patients were classified as DM
(n = 45, group 3), including 5 patients met the criteria
for DM after they had begun PD. Besides differing in the
criteria met for MetS, patients in group 2 also had
higher levels of albumin and CRP, higher AI1 and AI2,
more abdominal fat indicators, and lower levels of D/P
creatinine and nPCR than patients in group 1 (Table 1).
DM patients (group 3) had more significant histories of
coronary artery disease (CAD), older ages, higher BMIs,
higher glucose loads, increased AI1 and AI2, and more
abdominal fat than patients in group 1. The PD duration
in the DM patients was the shortest and the nPCR was
the lowest of the 3 groups. These results indicate that
MetS patients are similar to DM patients in that they
have higher AIs and CRP levels, and more abdominal
fat, but MetS patients have less significant CAD
histories.Predictors for VFA, SFA, and TFA
Because DM significantly influences lipid and carbohy-
drate metabolism and fat distribution, we analyzed the
correlation between VFA and other variables in the
groups. Because CRP was not evenly distributed, we log-
transformed the CRP data for analysis. We applied the
Pearson’s correlation to define the relationship between
CRP levels and fat components. In non-DM patients,
CRP levels had a significant positive correlation with
VFA (r = 0.396, P < 0.001; Figure 1A), SFA (r = 0.431, P <
0.001; Figure 1B), and TFA (r = 0.476, P < 0.001;
Figure 1C). Otherwise, fat area correlated proportionally
with age, body weight (BW), CHO, TG, AIs, and fasting
glucose (Table 2). These abdominal fat parameters were
inversely correlated with peritoneal KT/V, creatinine,
and nPCR. The cardiothoracic ratio, which is inversely
related to heart function, also had a positive correlation
with abdominal fat. The use of RAS blockers had a nega-
tive correlation with abdominal fat, whereas the use of
beta blockers had a positive one (Table 2). In general,
the correlations were similar in DM patients, except that
CRP level and type of antihypertensive medication had
no correlations with abdominal fat.
In addition, we used multiple linear regression ana-
lysis to determine independent predictors, after
adjusting for age, sex, and BW. In non-DM patients,
creatinine associated negatively with all fat area indi-
cators (Table 3A). CRP levels were associated posi-
tively with VFA and TFA. The use of RAS blockers
negatively predicted VFA, whereas the use of beta
blockers associated positively with SFA. Both types of
medications correlated with TFA. In DM patients, the
fat area was associated only with age, sex, and lipid
parameters (Table 3B).
Table 4 Comparison of glucose exposure, inflammation, and CV comorbidity among non-DM PD patients categorized according to each criterion of metabolic
syndrome
Triglyceride High density lipoprotein Hypertension Body mass index Glucose
− + − + − + − + − +
69 69 52 86 22 116 113 25 94 44
CRP (mg/dL) 1.0 ± 2.6 1.2 ± 2.3 1.0 ± 2.4 1.2 ± 2.5* 2.0 ± 3.7 1.0 ± 2.1* 0.9 ± 2.0 2.0 ± 3.7* 1.0 ± 2.1 1.4 ± 3.0*
VFA (cm2/[kg/m2]) 3.1 ± 1.8 4.6 ± 1.9* 3.2 ± 1.8 4.2 ± 2.0* 4.6 ± 2.0 3.7 ± 2.0 3.5 ± 1.8 5.4 ± 1.9* 3.6 ± 2.1 4.4 ± 1.8*
Cardiothoracic ratio (%) 48 ± 6 49 ± 7 48 ± 6 49 ± 7 47 ± 7 49 ± 7 48 ± 7 50 ± 5 48 ± 7 50 ± 7
Albumin (g/dL) 3.9 ± 0.3 4.1 ± 0.3* 3.9 ± 0.4 4.1 ± 0.3* 4.0 ± 0.3 4.0 ± 0.4 4.0 ± 0.3 4.1 ± 0.4 4.0 ± 0.3 4.1 ± 0.4
Renal KT/V 0.21 ± 0.32 0.19 ± 0.32 0.30 ± 0.37 0.14 ± 0.28* 0.10 ± 0.16 0.22 ± 0.34* 0.17 ± 0.29 0.32 ± 0.44* 0.20 ± 0.32 0.21 ± 0.32
Glucose load (g/dL) 1.88 ± 0.33 1.86 ± 0.31 1.80 ± 0.29 1.91 ± 0.33 1.82 ± 0.31 1.88 ± 0.32 1.86 ± 0.32 1.89 ± 0.34 1.87 ± 0.33 1.85 ± 0.29
Glucose exposure (kg/year) 56 ± 20 53 ± 19 49 ± 19 58 ± 20* 53 ± 12 55 ± 21 54 ± 20 57 ± 21 55 ± 20 53 ± 19
CAD History 7 7 3 11 3 11 12 2 8 6
CVD Event 5 5 3 7 1 9 8 2 7 3
*P < 0.05 compared by student t-test, non-parametric t-test, or Chi-test.


























Figure 3 Kaplan-Meir survival analysis was used to compare
the duration of time to mortality (A), technique failure (B), and
hospitalization (C) among PD patients. All patients were
categorized into group 1 non-MetS, group 2 MetS and group 3 DM
patients. There was no significant difference among these three
groups except that DM patients had shorter time to hospitalization.
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Since fat area correlated with lipid and glucose me-
tabolism, both of which reflect metabolic dysfunction,
we analyzed the fat area in all PD patients without
DM and categorized the patients into 6 groups based
on the number of criteria they met for MetS. Four
patients did not meet any criteria of MetS, 35 fulfilled
1 criterion, 39 fulfilled 2 criteria, 45 fulfilled 3 cri-
teria, 44 fulfilled 4 criteria, and 16 fulfilled all 5 MetS
criteria. VFA, SFA, and TFA increased as the number
of criteria met increased (Figure 2; P < 0.001 by
ANOVA).
Effects of MetS on PD patient outcomes
PD patients without DM were analyzed further for each
criterion of MetS fulfilled by comparing VFA, CRP, PD
dialysate glucose load, annual glucose exposure, CAD
history, and CVD comorbidity. CRP levels were higher
in patients who fulfilled any single criterion except for
hypertension (Table 4). PD glucose load and exposure
were similar for each criterion. Finally, none of the cri-
teria for MetS resulted in significant differences in heart
size, CAD history, or follow-up CVD events.
The Kaplan-Meier survival analysis was used to com-
pare survival among non-MetS, MetS, and DM patients.
Patients with DM had the shortest survival, but MetS
did not have an effect on survival outcome (Figure 2).
Discussion
In this 3-year prospective study, we have demon-
strated that VFA, SFA, and TFA increased with the
number of MetS criteria met in PD patients. VFA
and MetS were also associated with inflammation in
PD patients without DM. The use of both RAS
blockers and beta blockers was associated with the
area of abdominal fat. However, neither MetS nor ab-
dominal fat was associated with technique failure,
hospitalization, CVD events, or mortality.
It has been reported that renal failure, especially in as-
sociation with DM, is associated with the occurrence of
CVD events and is a predictor of poor prognosis in pa-
tients with acute myocardial infarction [26,27]. MetS is
similar to DM in insulin resistance and abnormal glu-
cose and lipid metabolism, and MetS was diagnosed in
nearly half of the non-DM PD patients in this study and
has been observed in a higher percentage of patients in
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cause one-third of PD patients without DM are glucose
intolerant [15]. In addition, PD elevated the daily dialys-
ate glucose load by 1.86 g/dL and the annual glucose ex-
posure by 53–56 kg (Table 1), which may affect patients
with low HDL levels (Table 4). As in the generalized
population [28], PD patients showed an association be-
tween MetS and abdominal fat.
Although waist circumference had been reported to
be a reliable marker of abdominal adiposity in PD pa-
tients [29], waist circumference may be distorted by
PD fluid instillation. Fat area measured by the CT
scan, as in the present study, would appear to be the
more accurate method of measurement. Abdominal
fat area increased with the number of criteria fulfilled
in PD patients (Figure 2).
MetS in PD patients was also related to inflammation,
which is the primary cause of obesity-linked insulin resist-
ance and not only a mere consequence of obesity [30]. Fat
accumulation has been linked to inflammation that is char-
acterized by increased CRP levels [31], as shown in the
present study. The inflammatory response can be initiated
from fat stores [30], or due to uremia, dialysis, or infection
[32]. In HD patients, abdominal fat deposition has been
linked to inflammation and subsequent increases in mortal-
ity risk [33]. In PD patients, visceral fat level was an inde-
pendent predictor of pulse wave velocity and brachial artery
flow–mediated dilatation, and was also one of the risk fac-
tors for cardiovascular disease in this population [34]. Our
previous study also revealed that larger amounts of adipose
tissue were associated with higher serum levels of pro-
inflammatory markers and were, therefore, related to the left
ventricular diastolic dysfunction [35].
In our study on PD patients, CRP positively corre-
lated with VFA, SFA, and TFA (Table 2) and
remained an independent predictor of fat area after
adjusting for sex, age, and BW (Table 3). These re-
sults further confirm the relationship between abdom-
inal fat and inflammation in non-DM patients.
However, increased abdominal fat and MetS did not
influence survival outcomes (Figure 3).
In total, 116 out of 138 (84%) PD patients with hyperten-
sion in our study were prescribed medications to control
their BP. However, commonly used antihypertensive agents
have different effects on insulin sensitivity, which is associ-
ated with abdominal fat. Plasma angiotensin is associated
with adiposity [36], and RAS blockers can improve glucose
homeostasis [37] and reduce abdominal fat [19,20]. Al-
though we conducted a retrospective analysis of patients’
medication use, our PD patients appeared to experience
similar RAS blocker–induced effects on VFA. In contrast,
traditional beta blockers are known to worsen glucose
homeostasis [38]. In the present study, a new generation
beta blocker, nebivolol, which may benefit insulin sensitivity[21], was not used. Beta blockers were positively correlated
with SFA. Insulin sensitivity might be influenced by these
drugs and the abdominal fat accumulation that follows their
use, but to date, their clinical significance in PD patients re-
mains unclear.
This statement raises the question of why CRP-associated
abdominal fat does not predict survival in PD patients. Our
data may explain this phenomenon. First, BMI had a posi-
tive correlation with area of abdominal fat; however, the fat
area was adjusted for BMI in this study (Table 2). The in-
verse association between BMI and mortality in dialysis pa-
tients has been established [39]. Second, in addition to CRP
and age, albumin was positively correlated with VFA
(Table 3). Albumin has been shown to be an important pre-
dictor of survival in dialysis patients [40]. With respect to
the role of MetS, the analysis of the MetS criteria showed
that each criterion did not have a uniform effect in PD pa-
tients (Table 4). This study population was composed of
fewer obese patients and more hypertensive patients. Obes-
ity has been associated with better clinical outcomes in dia-
lysis patients. Another inverse correlation was also noted
between blood pressure and CRP levels, with hypertensive
patients having lower CRP levels than normotensive pa-
tients. Therefore, these multiple associations complicate the
effects of MetS and abdominal fat on PD patient survival.
The present study has certain limitations. First, the follow-
up period is too short to monitor longer-term outcomes
such as CVD events and mortality. Second, the small sample
size may have influenced the statistical analysis. Since the
overall CVD event rate was low in the present study, more
patients should be recruited in future studies to determine
the effect of abdominal fat area on the CVD event rate. Fi-
nally, related to the survival analysis, all the parameters, in-
cluding VFA, might vary during the study period. As it will
not be feasible to measure VFA at regular intervals with CT
scans, this will remain a limitation in future studies on sur-
vival outcomes.
In conclusion, both abdominal fat area and MetS
are associated with inflammation in PD patients. Al-
though the mechanism of the association remains un-
clear, the use of RAS blockers and beta blockers are
associated with abdominal fat area in PD patients
without DM. Abdominal fat area and MetS are asso-
ciated with BMI and nutritional status, and these had
an effect opposite to that of inflammation on patient
outcomes. These complex associations decrease the
capacity of abdominal fat and MetS to predict PD pa-
tient outcomes accurately.
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